Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up2.580 +0.040 (+1.575%)
Others

21/10/2020 11:31

Sino Biopharm (01177) anti-tumour drug passes evaluation

[ET Net News Agency, 21 October 2020] Sino Biopharmaceutical Limited (01177) said the
anti-tumour drug "Capecitabine Tablets" (brand name: Shoufu) of the group has obtained the
notice of approval of supplemental applications issued by the National Medical Products
Administration of the People's Republic of China and has passed the Consistency of Quality
and Efficacy Evaluation for Generic Drugs. The indications of Shoufu are for the adjuvant
chemotherapy of colon cancer, combination chemotherapy for colorectal cancer and breast
cancer, single-agent chemotherapy for breast cancer, and adjuvant therapy for gastric
cancer.
Capecitabine is an oral cytotoxic agent with selective activity on tumour cells. It has
no cytotoxicity, but is converted into 5-fluorouracil (5-FU) under the action of enzymes
in the body to exert anti-tumour effects. (RC)

Remark: Real time quote last updated: 23/04/2024 15:05
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.